ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CTMX CytomX Therapeutics Inc

1.3808
-0.0792 (-5.42%)
Jun 14 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 1,635,319
Bid Price 1.38
Ask Price 1.70
News (1)
Day High 1.485

Low
1.04

52 Week Range

High
5.85

Day Low 1.375
Share Name Share Symbol Market Stock Type
CytomX Therapeutics Inc CTMX NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.0792 -5.42% 1.3808 23:00:04
Open Price Low Price High Price Close Price Previous Close
1.45 1.375 1.485 1.38 1.46
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
5,766 1,635,319 US$ 1.42 US$ 2,320,493 - 1.04 - 5.85
Last Trade Type Quantity Price Currency
18:59:57 1 US$ 1.40 USD

CytomX Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
93.46M 67.72M - 101.21M -569k -0.01 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

CytomX Therapeutics News

Date Time Source News Article
6/14/202415:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
5/22/202415:05GlobeNewswire Inc.CytomX Therapeutics to Present at the Jefferies Global..
5/17/202416:36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
5/17/202416:36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
5/17/202416:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
5/17/202416:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
5/17/202416:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
5/17/202415:01Edgar (US Regulatory)Form 8-K - Current report
5/16/202415:15GlobeNewswire Inc.CytomX Therapeutics Announces New Employment Inducement..
5/13/202415:00Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial..
5/08/202415:41Edgar (US Regulatory)Form 8-K - Current report
5/08/202415:10GlobeNewswire Inc.CytomX Therapeutics Reports First Quarter 2024 Financial..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No CTMX Message Board. Create One! See More Posts on CTMX Message Board See More Message Board Posts

Historical CTMX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.661.691.3751.523,153,543-0.2792-16.82%
1 Month1.951.971.3751.682,171,094-0.5692-29.19%
3 Months2.215.851.3753.967,045,451-0.8292-37.52%
6 Months1.455.851.323.753,711,679-0.0692-4.77%
1 Year1.655.851.043.611,960,146-0.2692-16.32%
3 Years7.227.52991.043.171,478,913-5.84-80.88%
5 Years10.1915.441.044.171,118,176-8.81-86.45%

CytomX Therapeutics Description

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platform. The company probody technology platform to create proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. The company focuses on developing Probody therapeutics which addresses clinically-validated cancer targets in immuno-oncology that are difficult to drug and lead to concerns about damage to healthy tissues or toxicities.

Your Recent History

Delayed Upgrade Clock